It's not safe for people with heart disease or certain other conditions
Talk to your cancer care team about the best way to manage your side effects
View on PubMed Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management Expert review characterising retatrutide as a first-in-class GIP, GLP-1, and glucagon triple receptor agonist, detailing its mechanism of action, pharmacokinetics, and the clinical significance of adding glucagon receptor agonism to produce superior weight loss to dual agonists (Expert Opin Investig Drugs, 2023)
Customized packaging, Logo, OEM, etc
, , ,
However, these drugs are challenged with long-term effectiveness, as most patients taking Semaglutide regain two-thirds of their lost weight after one year of withdrawal (Wilding et al